Hrt Financial LP Rubius Therapeutics, Inc. Transaction History

Hrt Financial LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.46 - $1.29 $123,062 - $345,109	-267,527 Reduced 92.91%	20,425 $8,000
Q2 2022 Aug 12, 2022	BUY	$0.79 - $5.98 $139,410 - $1.06 Million	176,469 Added 158.29%	287,952 $244,000
Q1 2022 May 16, 2022	BUY	$4.25 - $10.4 $380,876 - $932,027	89,618 Added 409.87%	111,483 $614,000
Q4 2021 Feb 14, 2022	SELL	$9.68 - $17.74 $28,643 - $52,492	-2,959 Reduced 11.92%	21,865 $211,000
Q3 2021 Nov 15, 2021	BUY	$17.6 - $25.91 $436,902 - $643,189	24,824 New	24,824 $443,000
Q4 2020 Feb 16, 2021	SELL	$4.23 - $8.73 $194,622 - $401,667	-46,010 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$4.65 - $6.25 $213,946 - $287,562	46,010 New	46,010 $230,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.